Signostics is pioneering smart ultrasound devices to enhance imaging and clinical decision making in urologic care as the global leader of ultrasound innovation.
Clinicians had long been accustomed to using conventional handheld scanners to measure bladder volume. From their home base in Adelaide, Australia, the technologists at Signostics recognized how much more could be achieved through adoption of advances in microprocessing and software.
After the global commercialization of its first device in 2009, Signostics developed the SignosRT handheld ultrasound in 2013 and the SignosRT Bladder Scanner in 2014 – both offering groundbreaking accuracy, ease of use, and affordability.
Now, leveraging science from current day computer vision algorithms, Signostics technology has made a revolutionary advance with the introduction of Uscan – the world’s first smart mobile-connected ultrasound device targeted at urologic care.
Now under the leadership of CEO and industry pioneer Kevin Goodwin, Signostics has gained recognition and $35 million in funding though a capital commitment from the global investment firm KKR.
KKR’s investment is enabling Signostics to assemble the talent and infrastructure for the next wave of intelligent point-of-care ultrasound diagnostics, with enhanced feature recognition and analysis,
Signostics seeks to place the power of smart ultrasound diagnostics in the hands of more practitioners and facilities everywhere, to benefit an ever widening range of patients.
Latest funding size
Time since last funding
|about 2 years|
|Terra Rossa Capital, Brandon Capital Partners, BridgeLane Capital, Playford Capital, KKR & Co. (Kohlberg Kravis Roberts & Co.)|